Biotech Showcase™ 2016: C4 Therapeutics targets protein degradation

February 2, 2016
Finding a way to trick the ubiquitin proteasome system, C4 Therapeutics, a spin-out from Harvard's Dana-Farber Cancer Institute, has developed a way to target any disease-causing protein for degradation. Fresh from announcing the creation of the company, a USD 73 million series A financing, and a deal with Roche which has a potential biodollar value north of USD 750 million, C4 Therapeutics co-founder and executive chairman Marc Cohen explains to Informa Pharma Insights global director of content Mike Ward how the approach works. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Biotech Showcase™ 2016: Interview: Abeona breaking into rare diseases
Biotech Showcase™ 2016: Interview: Abeona breaking into rare diseases

Three-year-old Abeona Therapeutics is poised to enter the clinic with its lead gene therapy programs target...

Next Video
Biotech Showcase™ 2016: Interview: Canaan Partners outlines funding priorities
Biotech Showcase™ 2016: Interview: Canaan Partners outlines funding priorities

After raising its 10th fund in 2014, Canaan Partners has been actively investing in early stage US biopharm...